An interventional study of Implantation of the Solia CSP S pacing lead for LBBAP in Cardiac Pacing, Artificial, Cardiac Pacemaker, Artificial and Cardiac Resynchronization Therapy Devices, sponsored by Biotronik SE & Co. KG. Active, not recruiting at 14 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Biotronik SE & Co. KG · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Bradycardia by Biotronik SE & Co. KG — 3 open to participants now, 4 under way, none of them phase 3. Bradycardia · Biotronik SE & Co. KG.
Among the 15 studies in Bradycardia by Biotronik SE & Co. KG, this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is one of 8 with no phase, and was the 11th registered.
317 studies on the registry are indexed under Bradycardia; 71 are open to participants now.
Browse Bradycardia studies →3 of the 15 studies in Bradycardia by Biotronik SE & Co. KG are open now, in 12 countries. Recruiting first, the newest first:
Biotronik SE & Co. KG · Sites in Australia, Austria, Czechia and 10 more countries
Ages 18+
Biotronik, Inc. · Sites in United States, Australia, Austria and 5 more countries
Ages 18+
Biotronik SE & Co. KG · Sites in Australia, Czechia, France and 6 more countries
Ages 18+
By country, each count listing its studies:
Of the 51 Bradycardia studies recruiting now, 34 (67%) set no upper age limit and 9 (18%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 152 is above the median of 100 across 187 interventional studies indexed under Bradycardia.
Median enrollment 193 across the 10 interventional studies, 571 across the 5 observational. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
Biotronik SE & Co. KG is the lead sponsor of 83 studies on the registry; 6 are open to participants now.
2 of the studies in Bradycardia by Biotronik SE & Co. KG that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07118358Biotronik, Inc.BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System | 2027-03 |
| NCT04075084Biotronik SE & Co. KGObservation of Clinical Routine Care for Patients With BIOTRONIK Implantable Cardiac Monitors (ICMs) | 2027-05-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Bradycardia by Biotronik SE & Co. KG, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical study is to test the clinical safety and performance of the Amvia pacemakers and the Solia CSP S lead when used for left bundle branch area pacing (LBBAP). The patient population consist of patients with cardiac pacemaker indication or cardiac resynchronization therapy indication and intended for implantation of a system with left bundle branch area stimulation. Participants will visit sites at enrollment in the study, at implantation and pre-hospital discharge, 1-, 6- and 12-month follow-up visits. Additional annual follow-up(s) may apply until study termination after regulatory approval of Solia CSP S. The total duration of the clinical investigation is expected to be until September 2027, with last patient out (LPO). During the visits the regular pacemaker and lead measurement are performed. A 12-lead ECG is recorded to document intrinsic and ventricularly paced heart rhythm to assess left bundle branch area pacing. Programming of the pacemakers will be done according to the participant´s therapeutical needs.
The study will be conducted in approximately 18 sites in Europe, Australia and New Zealand where more than one physician per site are expected to participate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For patient enrollment in the study all of the following inclusion criteria have to be fulfilled at the time of enrollment:
Exclusion Criteria:
Enrollment of a patient is not permitted if at least one of the following criteria is fulfilled:
All patients with successful implantation of Amvia pacemaker and a lead in a position intended for LBBA pacing.
All patients with successful implantation of a Solia CSP S lead in LBB area. Additionally, all patients with a non-successful Solia CSP S implantation attempt in which an ADE (adverse device effect) or SADE (serious adverse device effect) related to the Solia CSP S lead occurred.
Device: Implantation of the Solia CSP S pacing lead for LBBAP
Left bundle branch area pacing using a Solia CSP S lead
Amvia related SADE-d free rate
rate of serious adverse device effects possible, probable or causal related to the Amvia pacemaker
Time frame: 6 months (183 days) after implantation
Solia CSP S related SADE-d free rate
rate of serious adverse device effects possible, probable or causal related to the Solia CSP S lead
Time frame: 6 months (183 days) after implantation
Amvia related SADE-d free rate
Rate of serious adverse device effects possible, probable or causal related to the Amvia pacemaker
Time frame: 12 months (365 days) after implantation
Solia CSP S related SADE-d free rate
Rate of serious adverse device effects possible, probable or causal related to the Solia CSP S lead
Time frame: 12 months (365 days) after implantation
Rate of successful acute CSP implantation of Solia CSP S
All implantations, in which the investigator decides to leave the Solia CSP S pacing lead permanently in the conduction system, are counted as acute success.
Time frame: At the day of implantation
Sensing performance
Investigators will be asked whether the sensing is adequate (yes/no decision)
Time frame: At the day of implantation and at the date of each in-office patient follow-up visit (1-, 6-, 12-month follow-up, and annual follow-up*) * please refer to study duration in study description section
Pacing performance
Investigators will be asked whether the pacing is adequate (yes/no decision)
Time frame: At the day of implantation and at the date of each in-office patient follow-up visit (1-, 6-, 12-month follow-up, and annual follow-up*) * please refer to study duration in study description section
Physiologic ventricular excitation
Investigators are asked to assess whether pacing in the left bundle branch area is still present based on the 12-lead ECG recording
Time frame: At the day of implantation and at the date of each in-office patient follow-up visit (1-, 6-, 12-month follow-up, and annual follow-up*) * please refer to study duration in study description section
Mid-term change in LVEF
Collection of left ventricular ejection fraction (LVEF) values
Time frame: At baseline, at the 6-month follow-up, at the 12-month follow-up and at all following annual in-office follow-ups*, if applicable; * please refer to study duration in study description section
Mid-term change in LVESV
Collection of left ventricular ejection systolic volume (LVESV) values
Time frame: At baseline, at the 6-month follow-up, at the 12-month follow-up and at all following annual in-office follow-ups*, if applicable; * please refer to study duration in study description section
Mid-term change in quality of life, EQ-5D-5L (EuroQol) questionnaire
Collection of health-related quality of life questionnaires from the patient to monitor mid-term changes in the quality of life, analysis and reporting according to EuroQol methodology
Time frame: At baseline after patient enrollment prior to implantation, at the date of 6-month follow-up, at the 12-month follow-up and at all following annual in-office follow-ups*, if applicable; * please refer to study duration in study description section
Mid-term change in quality of life, SF-36 (Short Form Health Survey) questionnaire
Collection of health-related quality of life questionnaires from the patient to monitor mid-term changes in the quality of life, analysis and reporting according to item short form health survey (SF-36) standard methodology
Time frame: At baseline after patient enrollment prior to implantation, at the date of 6-month follow-up, at the 12-month follow-up and at all following annual in-office follow-ups*, if applicable; * please refer to study duration in study description section
Plan to share: Yes — Anonymized data may be shared with qualified healthcare practitioners or academic researchers upon request and with permission of BIOTRONIK. Requests shall be sent to the Clinical Research Department of BIOTRONIK.
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Oct 2026, 24 months after the start.
Of 36 industry-sponsored interventional studies with no phase under Bradycardia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's planned 24 months is above that.
Counting every sponsor, half of 83 studies reached it within 21 months; a quarter within 12 and three quarters within 38.
Primary completion moved once since we started tracking on Sep 25, 2026: Apr 2026 → Oct 2026, on Oct 1, 2026.
Completion moved once since we started tracking on Sep 25, 2026: Sep 2027 → Dec 2026, on Oct 21, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.